Clinical Trial

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Name: Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients — clinical trial record (NCT06407232)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.

Trial Details

NCT Number	NCT06407232
Lead Sponsor	University of Wisconsin, Madison Collaborators: Merck Sharp & Dohme LLC
Conditions	Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant
Enrollment	90 participants
Start Date	2024-08-08
Primary Completion	2027-08 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-11